A CT-based radiomics signature for preoperative discrimination between high and low expression of programmed death ligand 1 in head and neck squamous cell carcinoma

2022 ◽  
Vol 146 ◽  
pp. 110093
Author(s):  
Ying-mei Zheng ◽  
Jin-feng Zhan ◽  
Ming-gang Yuan ◽  
Feng Hou ◽  
Gang Jiang ◽  
...  
Oncotarget ◽  
2017 ◽  
Vol 8 (58) ◽  
pp. 97920-97927 ◽  
Author(s):  
Chan-Young Ock ◽  
Sehui Kim ◽  
Bhumsuk Keam ◽  
Soyeon Kim ◽  
Yong-Oon Ahn ◽  
...  

2018 ◽  
Vol 142 (6) ◽  
pp. 719-720
Author(s):  
Christine Kunkle ◽  
Flavia G Rosado

Context.— There has been increasing interest in understanding the role of programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) pathway in cancer biology and its clinical significance in cancer therapy. Objective.— To discuss the studies of the PD-1/PD-L1 pathway in human papillomavirus–positive head and neck squamous cell carcinoma, focusing on the pathogenesis of cancer, characterization of the tumor microenvironment, and the effect of such studies in laboratory medicine. Data sources.— Data sources included peer-reviewed literature and reputable online sources. Conclusions.— To date, there are few studies of PD-1 and PD-L1 in human papillomavirus–positive head and neck squamous cell carcinoma. There is evidence that the PD-1/PD-L1 pathway has a role in this type of cancer; however, further studies are needed to better characterize the effect of the human papillomavirus and its use as a marker of therapy response.


Sign in / Sign up

Export Citation Format

Share Document